RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Thanigaivelan Kanagasabai to Animals

This is a "connection" page, showing publications Thanigaivelan Kanagasabai has written about Animals.
Connection Strength

0.205
  1. Kanagasabai T, Li G, Shen TH, Gladoun N, Castillo-Martin M, Celada SI, Xie Y, Brown LK, Mark ZA, Ochieng J, Ballard BR, Cordon-Cardo C, Adunyah SE, Jin R, Matusik RJ, Chen Z. MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway. Cancer Lett. 2022 01 28; 525:46-54.
    View in: PubMed
    Score: 0.062
  2. Rathinavelu A, Alhazzani K, Dhandayuthapani S, Kanagasabai T. Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor-specific inhibitor. Tumour Biol. 2017 Nov; 39(11):1010428317726841.
    View in: PubMed
    Score: 0.047
  3. Farris T, Gonz?lez-Ochoa S, Mohammed M, Rajakaruna H, Tonello J, Kanagasabai T, Korolkova O, Shimamoto A, Ivanova A, Shanker A. Loss of Mitochondrial Tusc2/Fus1 Triggers a Brain Pro-Inflammatory Microenvironment and Early Spatial Memory Impairment. Int J Mol Sci. 2024 Jul 05; 25(13).
    View in: PubMed
    Score: 0.019
  4. Evans JV, Suman S, Goruganthu MUL, Tchekneva EE, Guan S, Arasada RR, Antonucci A, Piao L, Ilgisonis I, Bobko AA, Driesschaert B, Uzhachenko RV, Hoyd R, Samouilov A, Amann J, Wu R, Wei L, Pallerla A, Ryzhov SV, Feoktistov I, Park KP, Kikuchi T, Castro J, Ivanova AV, Kanagasabai T, Owen DH, Spakowicz DJ, Zweier JL, Carbone DP, Novitskiy SV, Khramtsov VV, Shanker A, Dikov MM. Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression. J Natl Cancer Inst. 2023 11 08; 115(11):1404-1419.
    View in: PubMed
    Score: 0.018
  5. Celada SI, Li G, Celada LJ, Lu W, Kanagasabai T, Feng W, Cao Z, Salsabeel N, Mao N, Brown LK, Mark ZA, Izban MG, Ballard BR, Zhou X, Adunyah SE, Matusik RJ, Wang X, Chen Z. Lysosome-dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer. Mol Oncol. 2023 10; 17(10):2126-2146.
    View in: PubMed
    Score: 0.018
  6. Tewary P, Brooks AD, Xu YM, Wijeratne EMK, Babyak AL, Back TC, Chari R, Evans CN, Henrich CJ, Meyer TJ, Edmondson EF, de Aquino MTP, Kanagasabai T, Shanker A, Gunatilaka AAL, Sayers TJ. Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins. Cancer Res. 2021 06 15; 81(12):3374-3386.
    View in: PubMed
    Score: 0.015
  7. Li G, Kanagasabai T, Lu W, Zou MR, Zhang SM, Celada SI, Izban MG, Liu Q, Lu T, Ballard BR, Zhou X, Adunyah SE, Matusik RJ, Yan Q, Chen Z. KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis. Cancer Res. 2020 11 01; 80(21):4633-4643.
    View in: PubMed
    Score: 0.014
  8. Rathinavelu A, Kanagasabai T, Dhandayuthapani S, Alhazzani K. Anti-angiogenic and pro-apoptotic effects of a small-molecule JFD-WS in in vitro and breast cancer xenograft mouse models. Oncol Rep. 2018 Apr; 39(4):1711-1724.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support